These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11939684)

  • 61. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
    Dang CH; Durkalski VL; Nappi JM
    Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bivalent direct thrombin inhibitors: hirudin and bivalirudin.
    Warkentin TE
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):105-25. PubMed ID: 15171961
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thrombin inhibitor approved for anticoagulation during angioplasty.
    Lieder TR
    Am J Health Syst Pharm; 2001 Mar; 58(5):363. PubMed ID: 11258166
    [No Abstract]   [Full Text] [Related]  

  • 64. Lepirudin for heparin-induced thrombocytopenia.
    Med Lett Drugs Ther; 1998 Sep; 40(1036):94-5. PubMed ID: 9774965
    [No Abstract]   [Full Text] [Related]  

  • 65. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic levels of recombinant hirudin.
    Nowak G
    Haemostasis; 1992; 22(6):348-50. PubMed ID: 1301038
    [No Abstract]   [Full Text] [Related]  

  • 67. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
    Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.
    Warkentin TE
    Thromb Res; 2003 May; 110(2-3):73-82. PubMed ID: 12893020
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.
    Lubenow N; Greinacher A
    Am J Cardiovasc Drugs; 2001; 1(6):429-43. PubMed ID: 14728002
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Essentials of anticoagulation in hemodialysis.
    Fischer KG
    Hemodial Int; 2007 Apr; 11(2):178-89. PubMed ID: 17403168
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparisons of argatroban to lepirudin and bivalirudin in the treatment of heparin-induced thrombocytopenia: a systematic review and meta-analysis.
    Sun Z; Lan X; Li S; Zhao H; Tang Z; Xi Y
    Int J Hematol; 2017 Oct; 106(4):476-483. PubMed ID: 28600720
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy.
    Mueller SW; MacLaren R; Fish DN; Kiser TH
    Ann Pharmacother; 2009 Jul; 43(7):1360-5. PubMed ID: 19584380
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anticoagulation for patients with heparin-induced thrombocytopenia using recombinant hirudin during cardiopulmonary bypass.
    Liu H; Fleming NW; Moore PG
    J Clin Anesth; 2002 Sep; 14(6):452-5. PubMed ID: 12393116
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin).
    Baumgärtel MW; Eichler P; Glöckner WM; Ranze O; Greinacher A
    Eur J Haematol; 2000 Aug; 65(2):148-9. PubMed ID: 10966178
    [No Abstract]   [Full Text] [Related]  

  • 75. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
    Seybert AL; Coons JC; Zerumsky K
    Pharmacotherapy; 2006 Feb; 26(2):229-41. PubMed ID: 16466327
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.
    Cardenas GA; Deitcher SR
    Mayo Clin Proc; 2005 Apr; 80(4):491-3. PubMed ID: 15819285
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
    Koster A; Loebe M; Hansen R; Bauer M; Mertzlufft F; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1278-83. PubMed ID: 10838548
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 80. R-hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic R-hirudin blood/plasma concentrations and respective dosages.
    Bucha E; Nowak G; Czerwinski R; Thieler H
    Clin Appl Thromb Hemost; 1999 Jul; 5(3):164-70. PubMed ID: 10726003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.